Route 92 Medical Secures $50 Million Growth Financing to Expand Revolutionary Stroke Treatment Technology
核心洞察
Route 92 Medical (搜索) raised $50 million in Series F-2 financing led by Novo Holdings (搜索) to accelerate global commercial expansion of its neurovascular intervention technologies.
The company's HiPoint Reperfusion System achieved the highest first pass effect ever reported in a randomized controlled endovascular stroke thrombectomy study through its SUMMIT MAX trial.
Route 92 Medical (搜索) became the first neurovascular intervention company to receive FDA clearance for direct aspiration with a super-bore 0.088-inch catheter following May 2025 approval.
Route 92 Medical (搜索), a privately held medical technology company focused on neurovascular intervention, announced the completion of a $50 million Series F-2 preferred stock financing round. Novo Holdings (搜索) led the investment, with new investor Sectoral Asset Management (搜索) joining existing investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group.
The financing will support Route 92 Medical (搜索)'s next phase of growth by accelerating global commercial expansion, advancing clinical evidence to broaden adoption of the company's neurovascular procedural approach, and investing in continued product innovation across its platform.
Clinical Breakthrough Drives Commercial Success
The funding announcement follows the successful completion of Route 92 Medical (搜索)'s SUMMIT MAX clinical trial (NCT05018650), a 250-patient, multicenter, prospective, randomized, and controlled endovascular stroke thrombectomy trial. The study evaluated the safety and efficacy of the HiPoint Reperfusion System featuring the company's Monopoint approach.
Data from the trial demonstrated favorable safety performance and achieved the highest first pass effect ever reported in a randomized, controlled endovascular stroke thrombectomy study. These results led to FDA submission of the investigational device exemption (IDE) trial data and subsequent regulatory approval.
"We've seen rapid growth in the adoption of our products over the past year, attributable to the clinical performance of procedures with our Monopoint approach, and the growth and dedication of our commercial organization," said Tony Chou, MD, Chief Executive Officer and Founder of Route 92 Medical (搜索). "We're on a mission to improve outcomes for patients suffering from acute ischemic stroke and our rapidly growing sales are a testament to the differentiated, physician-preferred attributes of our neurovascular thrombectomy solutions."
First-in-Class FDA Clearance
In May 2025, the HiPoint Reperfusion System received thrombectomy marketing clearance from the FDA, making Route 92 Medical (搜索) the first neurovascular intervention company to receive clearance for direct aspiration of a stroke-causing thrombus with a super-bore 0.088-inch catheter in the neurovasculature.
The HiPoint Reperfusion System features the Monopoint approach, described as the first "super-bore" aspiration catheter with a mono-axial procedural approach and a 0.088-inch inner diameter FDA-cleared for the treatment of large vessel occlusions, which cause many acute ischemic strokes.
Comprehensive Product Portfolio
Route 92 Medical (搜索)'s neurovascular portfolio extends beyond the HiPoint system to include a suite of purpose-built stroke treatment solutions: the HiPoint 70 Reperfusion System, FreeClimb 70 Reperfusion System, FreeClimb 54 Reperfusion System, and the FreeClimb 88 Access System. The company's products are designed to work harmoniously as complete systems to improve the efficiency of endovascular thrombectomy procedures, enabling clinicians to quickly restore blood flow to a patient's brain following acute ischemic stroke.
Investor Confidence in Market Position
"We believe Route 92 is setting new standards in neurovascular intervention, with Tenzing, HiPoint, and FreeClimb improving how physicians navigate complex procedures and treat ischemic stroke," said Noel Jee, Ph.D., Partner, Growth Investments, Novo Holdings (搜索). "Real-world experience validates the strength of these technologies, and we're excited to support the expansion to more physicians and the patients they treat."
Michael Sjöström, CFA, Co-Founder and Partner of Sectoral Asset Management (搜索), emphasized the company's growth potential: "We believe Route 92 Medical (搜索) is positioned for long-term growth with robust manufacturing capacity, a clearly defined market, and a well-differentiated product portfolio. Our investment aims to accelerate its commercial growth, helping the company reach many more hospitals and patients."
The company targets acute ischemic stroke, described as the most common type of stroke affecting patients today. Route 92 Medical (搜索) was founded by physicians and collaborates with leading neurovascular clinicians to address the biggest challenges in neurointervention through cutting-edge engineering and innovative product design.